headache
Less common
Acid or sour stomach
belching
difficulty in moving
heartburn
indigestion
joint pain
muscle aching or cramping
muscle pains or stiffness
nausea
rash
stomach discomfort, upset, or pain
trouble sleeping
unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
swollen joints
For Healthcare Professionals
Applies to verapamil: compounding powder, intravenous solution, oral capsule extended release, oral tablet, oral tablet extended release
Gastrointestinal
Constipation due to verapamil (the active ingredient contained in Calan) appears to be related to a delay of colonic transit and not to an effect on upper gastrointestinal transit.[Ref]
Gastrointestinal side effects have included constipation (up to 11.7%), nausea (up to 2.7%), dyspepsia (up to 2.7%), and diarrhea (up to 2.4%). Nausea (0.9%) and abdominal discomfort (0.6%) have been reported with intravenous verapamil. Nonobstructive, paralytic ileus (reversible upon discontinuation) has been reported infrequently. Diarrhea, dry mouth, gastrointestinal distress, and gingival hyperplasia have been reported during open trials/postmarketing experience.[Ref]
Cardiovascular
Cardiovascular side effects have included hypotension (up to 2.5%), new or worsened congestive heart failure (CHF) or pulmonary edema (negative inotropism; 1.8%), bradycardia (heart rate less than 50/minute; 1.4%), atrioventricular (AV) block (first-degree; up to 1.7%), AV block (total first-, second-, and third-degree; 1.2%), AV block (second- and third-degree; 0.8%), and postural hypotension (up to 0.4%). Symptomatic hypotension (1.5%), bradycardia (1.2%), and severe tachycardia (1%) have been reported with intravenous verapamil (the active ingredient contained in Calan) In studies related to control of